ExpreS2ion Biotechnologies: Enters term sheet on commercialization of malaria vaccines
ExpreS2ion Biotechnologies announced yesterday that the company has signed a term sheet with Serum Institute of India Private Limited (SIIPL), a leading global vaccine manufacturer. Upon execution of a definitive agreement, SIIPL will obtain rights to develop, manufacture, and commercialize the malaria vaccines currently in Phase I and Phase II together with the University of Oxford.
ExpreS2ion Biotechnologies disclosed that they will receive limited undisclosed development and regulatory milestone payments, if successful and launched, lower single-digit percentage royalties based on future net sales of these products.
This follows the update in the journal, The Lancet, that highlighted the clinical progress of the lead malaria vaccine candidate. The promising findings reported by the University of Oxford further validate the potential of these vaccine candidates for combatting malaria.
There is no information about whether the deal also involves financing to the partner, which could speed up the development process. In the latest company-sponsored report from Analysguiden, they had a value of SEK 0.2 per share probability adjusted assigned to the malaria pipeline based on a 10% probability of success. Further details about the commercialization could change this value expectations.
ExpreS2ion Biotechnologies is a Danish pharmaceutical company, which focuses on the development of vaccines through the use of its non-viral Drosophila S2 cells-based expression system.
Disclaimer: HC Andersen Capital receives payment from ExpreS2ion Biotechnologies for a Digital IR/Corporate Visibility subscription agreement. /Michael Friis, 08:00 (updated 08:56) AM, 17.10.2024.
Login required
This content is only available for logged in users
ExpreS2ion Biotech Holding
ExpreS2ion is a Danish-based biotech company listed in Sweden. The company develops a portfolio of vaccines for diseases such as COVID-19, influenza, and breast cancer through the use of its non-viral cell-based expression system, ExpreS2, which is recognized for handling protein challenges. ExpreS2ion has developed Expres2, which is a technology platform for efficient and fast non-clinical development and production of complex proteins for new vaccines and diagnostics. The company’s current primary product is the corona vaccine candidate, ABNCoV2 in phase 2, co-developed with its partner, AdaptVac of which ExpreS2ion owns 34%. The vaccine candidate has been licensed to Bavarian Nordic has global commercialization rights and responsibility for further clinical development of the vaccine and is expected to initiate phase 3 testing for the product candidate in the first half of 2022.
Read more on company page